2.
Compared with the unscreened group, the increased cost, acquired effect, utility and benefit of the screening group
| Screening group | Cumulative incidence
(1/100,000) |
Reduction in cumulative
risk of disease (%) |
Increased cost
(million RMB) |
LYS
(year) |
Increased
QALY (year) |
Benefit
(million RMB) |
| LBC, liquid-based cytology; HPV, human papillomavirus; LYS, life year saved; QALY, quality-adjusted life year. | ||||||
| LBC | ||||||
| Every 3 years | 1,021.23 | 31.77 | 31.68 | 616.18 | 2,165.25 | 158.50 |
| HPV | ||||||
| Every 3 years | 833.02 | 44.34 | 51.42 | 868.78 | 3,333.70 | 241.74 |
| Every 5 years | 920.26 | 38.51 | 34.25 | 761.57 | 2,813.18 | 212.56 |
| HPV+LBC | ||||||
| Every 3 years | 1,062.49 | 29.01 | 44.23 | 558.10 | 1,973.03 | 151.06 |
| Every 5 years | 1,158.07 | 22.62 | 28.57 | 444.61 | 1,526.83 | 122.17 |